Literature DB >> 29182703

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification.

M N Sabbagh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29182703      PMCID： PMC5724794          DOI： 10.14283/jpad.2017.24

Source DB:  PubMed          Journal:  J Prev Alzheimers Dis        ISSN： 2274-5807


× No keyword cloud information.
  7 in total

1.  Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.

Authors:  Eric Martineau; Janna M de Guzman; Lioudmila Rodionova; Xianqi Kong; Paul M Mayer; Ahmed M Aman
Journal:  J Am Soc Mass Spectrom       Date:  2010-05-31       Impact factor: 3.109

2.  Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.

Authors:  Seong Hye Choi; Sang Yun Kim; Hae Ri Na; Byung-Kun Kim; Dong Won Yang; Jay C Kwon; Mee Young Park
Journal:  Dement Geriatr Cogn Disord       Date:  2008-04-10       Impact factor: 2.959

3.  Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential.

Authors:  S Abushakra; A Porsteinsson; P Scheltens; C Sadowsky; B Vellas; J Cummings; S Gauthier; J A Hey; A Power; P Wang; L Shen; M Tolar
Journal:  J Prev Alzheimers Dis       Date:  2017

4.  Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis.

Authors:  Francine Gervais; Julie Paquette; Céline Morissette; Pascale Krzywkowski; Mathilde Yu; Mounia Azzi; Diane Lacombe; Xianqi Kong; Ahmed Aman; Julie Laurin; Walter A Szarek; Patrick Tremblay
Journal:  Neurobiol Aging       Date:  2006-05-03       Impact factor: 4.673

5.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

Authors:  Stephen Salloway; Reisa Sperling; Nick C Fox; Kaj Blennow; William Klunk; Murray Raskind; Marwan Sabbagh; Lawrence S Honig; Anton P Porsteinsson; Steven Ferris; Marcel Reichert; Nzeera Ketter; Bijan Nejadnik; Volkmar Guenzler; Maja Miloslavsky; Daniel Wang; Yuan Lu; Julia Lull; Iulia Cristina Tudor; Enchi Liu; Michael Grundman; Eric Yuen; Ronald Black; H Robert Brashear
Journal:  N Engl J Med       Date:  2014-01-23       Impact factor: 91.245

6.  Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study).

Authors:  Paul S Aisen; Serge Gauthier; Steven H Ferris; Daniel Saumier; Denis Haine; Denis Garceau; Anh Duong; Joyce Suhy; Joonmi Oh; Wan C Lau; John Sampalis
Journal:  Arch Med Sci       Date:  2011-03-08       Impact factor: 3.318

7.  Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.

Authors:  Petr Kocis; Martin Tolar; Jeremy Yu; William Sinko; Soumya Ray; Kaj Blennow; Howard Fillit; John A Hey
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749
  7 in total
  6 in total

Review 1.  Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential.

Authors:  Md Tanvir Kabir; Md Sahab Uddin; Philippe Jeandet; Talha Bin Emran; Saikat Mitra; Ghadeer M Albadrani; Amany A Sayed; Mohamed M Abdel-Daim; Jesus Simal-Gandara
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

2.  Surfen and oxalyl surfen decrease tau hyperphosphorylation and mitigate neuron deficits in vivo in a zebrafish model of tauopathy.

Authors:  Seyedeh Maryam Alavi Naini; Constantin Yanicostas; Rahma Hassan-Abdi; Sébastien Blondeel; Mohamed Bennis; Ryan J Weiss; Yitzhak Tor; Jeffrey D Esko; Nadia Soussi-Yanicostas
Journal:  Transl Neurodegener       Date:  2018-03-16       Impact factor: 8.014

Review 3.  Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?

Authors:  Yuan Dong; Xiaoheng Li; Jinbo Cheng; Lin Hou
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

Review 4.  Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer's Disease.

Authors:  Md Sahab Uddin; Md Tanvir Kabir; Md Sohanur Rahman; Tapan Behl; Philippe Jeandet; Ghulam Md Ashraf; Agnieszka Najda; May N Bin-Jumah; Hesham R El-Seedi; Mohamed M Abdel-Daim
Journal:  Int J Mol Sci       Date:  2020-08-14       Impact factor: 5.923

Review 5.  A Review on Tramiprosate (Homotaurine) in Alzheimer's Disease and Other Neurocognitive Disorders.

Authors:  Sagrario Manzano; Luis Agüera; Miquel Aguilar; Javier Olazarán
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

Review 6.  Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty.

Authors:  Nurul Husna Ibrahim; Mohamad Fairuz Yahaya; Wael Mohamed; Seong Lin Teoh; Chua Kien Hui; Jaya Kumar
Journal:  Front Pharmacol       Date:  2020-03-24       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.